US Patent Applications in Skin Care Actives and Formulations Published in 2012
US PROVISIONAL PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2012
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications published. Salient search
terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening, blemish removal, etc. This
category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavengers, "green" derived molecules and
compounds having unique sensory properties.

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2011



Application No.: US20120010146A1  Published: 12/Jan/2012

Title: COMPOSITE CONTAINING COLLAGEN AND ELASTIN AS A DERMAL EXPANDER AND TISSUE FILLER

Applicant/Assignee: HANCOCK JAFFE LABORATORIES, INC

Application No.: 13/127275   Filing Date: 03/Nov/2009

Abstract:

An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen, in other alternatives, the composition can further comprise hyaluronic acid, and one or more of the elastin, the collagen, and the hyaluronic acid, if present can be cross-linked, either intramolecularly or intermolecularly. The elastin, however, is the primary filler, even if collagen or hyaluronic acid are included in the composition

Priority: US2008-111637P Applic. Date: 2008-11-05; WO2009US63132 Applic. Date: 2009-11-03

Inventor: HAN BO [US]; NIMNI MARCEL E [US]


Application No.: US20120010149A1  Published: 12/Jan/2012

Title: PEPTIDE COMBINATION

Applicant/Assignee: GKL-BIOTEC AG

Application No.: 13/142931   Filing Date: 30/Dec/2009

Abstract:

The invention relates to a peptide combination characterized by peptides each having the same sequence length (SEQL), that can be produced from a mixture (A) comprising a number x of amino acids having a protected acid group or a number z of peptides having an acid group protected by means of a protecting group and an activated amino group, wherein the amino acids are present in the mixture (A) in particular adjustable molar ratios, and a mixture (B) comprising a number y of amino acids having an amino group protected by means of a protecting group, wherein the amino acid molar ratios of the mixture (B) are equal to the amino acid molar ratios of the mixture (A), and wherein the number x=y.

Priority: DE200810063256 Applic. Date: 2008-12-30; WO2009DE01819 Applic. Date: 2009-12-30

Inventor: KLETT-LOCH GUENTHER [CH]


Application No.: US20120010150A1  Published: 12/Jan/2012

Title: LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT

Applicant/Assignee: AGENNIX INCORPORATED

Application No.: 13/227871   Filing Date: 08/Sep/2011

Abstract:

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Priority: US2009-403250 Applic. Date: 2009-03-12; US2003-663258 Applic. Date: 2003-09-16; US2002-410981P Applic. Date: 2002-09-16

Inventor: ENGELMAYER JOSE [US]; VARADHACHARY ATUL [US]


Application No.: US20120014876A1  Published: 19/Jan/2012

Title: ANTAGONISTIC PEPTIDES FOR FRIZZLED-1 AND FRIZZLED-2

Applicant/Assignee: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHT

Application No.: 13/138537   Filing Date: 18/Feb/2010

Abstract:

The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.

Priority: EP20090154475 Applic. Date: 2009-03-05; WO2010EP52058 Applic. Date: 2010-02-18

Inventor: BLANKESTEIJN WESSEL MATTHIJS [NL]; LAEREMANS HILDE [NL]; HACKENG TILMAN MATHIAS [NL]


Application No.: US20120014886A1  Published: 19/Jan/2012

Title: SOOTHING COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE WHICH ACTIVATES HMG-COA REDUCTASE

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141338   Filing Date: 23/Dec/2009

Abstract:

The present invention relates to a soothing cosmetic or pharmaceutical composition comprising at least one peptide that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Lys-X2-(AA)p-R2 and sequence SEQ ID No. 1 to SEQ ID No. 10, in a physiologically suitable medium. The present invention further relates to the utilization of this novel peptide as a soothing active principle in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.

Priority: FR20080007366 Applic. Date: 2008-12-23; WO2009FR01478 Applic. Date: 2009-12-23

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20120021029A1  Published: 26/Jan/2012

Title: PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 13/257807   Filing Date: 16/Apr/2010

Abstract:

Peptides of general formula (I): R1-AA1-AA2-AA3-R2 (I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases of the skin and/or hair.

Priority: US2009-170891P Applic. Date: 2009-04-20; ES20090001012 Applic. Date: 2009-04-17; WO2010EP02348 Applic. Date: 2010-04-16

Inventor: GARCIA SANZ NURIA [ES]; VAN DEN NEST WIM [ES]; CARRENO SERRAIMA CRISTINA [ES]; FERRER MONTIEL ANTONIO [ES]; CEBRIAN PUCHE JUAN [ES]; ALMINANA DOMENECH NURIA [ES]


Application No.: US20120021078A1  Published: 26/Jan/2012

Title: NUTRITIONAL COMPOSITION COMPRISING AN APPLE EXTRACT AND REDUCING FOOD ALLERGY SYMPTOMS, ESPECIALLY IN CHILDREN

Applicant/Assignee: NESTEC S.A

Application No.: 13/260814   Filing Date: 23/Apr/2010

Abstract:

A complete nutritional composition comprising polyphenols is provided for reducing the symptoms of allergies originating from food allergens in young children or infants. Preferably the composition modulates the secondary prevention of allergies while not affecting significantly the primary prevention. The composition comprises an apple extract.

Priority: EP20090158980 Applic. Date: 2009-04-28; WO2010EP55431 Applic. Date: 2010-04-23

Inventor: HOLVOET SEBASTIEN [CH]; MERCENIER ANNICK [CH]; ZUERCHER ADRIAN [CH]


Application No.: US20120021987A1  Published: 26/Jan/2012

Title: Mucin 3 EGF-Like Domains

Applicant/Assignee: MUCIMED, INC

Application No.: 13/022307   Filing Date: 07/Feb/2011

Abstract:

The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.

Priority: US2007-596273 Applic. Date: 2007-07-23; WO2005US16794 Applic. Date: 2005-05-13; US2004-570722P Applic. Date: 2004-05-13

Inventor: HO SAMUEL B [US]; SHEKELS LAURIE L [US]


Application No.: US20120027705A1  Published: 02/Feb/2012

Title: ADMINISTRATION OF CELLS AND CELLULAR EXTRACTS FOR REJUVENATION

Applicant/Assignee: REGENICS AS

Application No.: 13/267022   Filing Date: 06/Oct/2011

Abstract:

The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.

Priority: US2007-801778 Applic. Date: 2007-05-11; US2006-799560P Applic. Date: 2006-05-11

Inventor: GAMMELSAETER RUNHILD [NO]; REMMEREIT JAN [NO]


Application No.: US20120027708A1  Published: 02/Feb/2012

Title: Organopolysiloxane Compositions And Their Production

Applicant/Assignee:

Application No.: 13/260277   Filing Date: 30/Mar/2010

Abstract:

This invention relates to the polymerization of organopolysiloxanes to form organopolysiloxanes of increased molecular weight and to the organopolysiloxane compositions thus produced. The organopolysiloxane is in admixture with a molten wax during the polymerization, thereby forming a blend of the wax with an organopolysiloxane of increased molecular weight. After the polymerisation reaction is completed, the reaction product can be cooled below the solidification temperature of the wax, for example down to room temperature. This yield a paste-like solid blend which is a very intimate dispersion of wax in organopolysiloxane or vice versa. The dispersion is surprisingly stable.

Priority: GB20090005488 Applic. Date: 2009-03-31; WO2010EP54221 Applic. Date: 2010-03-30

Inventor: DURAND BEATRICE [BE]; TONET GIADA [BE]; GIRBOUX ANNELISE [BE]; DAVIO DELPHINE [BE]; STAMMER ANDREAS [BE]


Application No.: US20120039902A1  Published: 16/Feb/2012

Title: Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo

Applicant/Assignee:

Application No.: 11/578215   Filing Date: 22/Apr/2005

Abstract:

The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.

Priority: EP20040009659 Applic. Date: 2004-04-23; US2004-581479P Applic. Date: 2004-06-21; WO2005EP04349 Applic. Date: 2005-04-22

Inventor: KROCZEK RICHARD [DE]


Application No.: US20120046217A1  Published: 23/Feb/2012

Title: TNF-alpha Antagonists Containing IGFBP5

Applicant/Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION

Application No.: 13/142700   Filing Date: 30/Jun/2009

Abstract:

The present invention relates to: TNF-[alpha] antagonists containing IGFBP5 protein, variants thereof, or fragments thereof

and the use of the TNF-[alpha] antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof

a vector containing the polynucleotide

a transformant containing the vector

and a method for screening a therapeutic agent for TNF-[alpha] overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Priority: KR20080138164 Applic. Date: 2008-12-31; WO2009KR03570 Applic. Date: 2009-06-30

Inventor: LEE JE-HO [KR]; HWANG JAE-RYOUNG [KR]; HUH JAE-HO [KR]


Application No.: US20120058069A1  Published: 08/Mar/2012

Title: Cationic Benzoxazine (Co)Polymers

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 13/292562   Filing Date: 09/Nov/2011

Abstract:

Cationic benzoxazine (co)polymers wherein at least 5% of all nitrogen atoms are in the form of quaternary nitrogen atoms, and to a method for producing said polymers. The invention also relates to a washing and cleaning agent, a textile treatment agent or a cosmetic agent containing at least one cationic benzoxazine (co)polymer according to the invention.

Priority: DE200910003032 Applic. Date: 2009-05-12; WO2010EP56178 Applic. Date: 2010-05-06

Inventor: TADEN ANDREAS [DE]; KREILING STEFAN [DE]; SCHOENFELD RAINER [DE]; BARRELEIRO PAULA [DE]; EITING THOMAS [DE]


Application No.: US20120058076A1  Published: 08/Mar/2012

Title: AESTHETIC TREATMENT OF SCARS AND AGING SKIN

Applicant/Assignee:

Application No.: 13/294116   Filing Date: 10/Nov/2011

Abstract:

Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.

Priority: ZA20080008004 Applic. Date: 2008-09-18; ZA20090004000 Applic. Date: 2009-06-08; US2009-554364 Applic. Date: 2009-09-04; US2008-094170P Applic. Date: 2008-09-04

Inventor: WIDGEROW ALAN DAVID [US]


Application No.: US20120058086A1  Published: 08/Mar/2012

Title: COMPOSITIONS, KITS, AND METHODS FOR PROMOTING ISCHEMIC AND DIABETIC WOUND HEALING

Applicant/Assignee:

Application No.: 13/138889   Filing Date: 09/Apr/2010

Abstract:

Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1[alpha] specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject include providing a therapeutically effective amount of a composition including E-selectin protein or a nucleic acid encoding E-selectin protein, and optionally, an agent that specifically upregulates E-selectin expression (e.g., SDF-1[alpha]). The methods can also include administering hyperbaric oxygen treatment to the subject. Administering the composition to the subject results in migration of bone marrow-derived progenitor cells to the wound, accelerated wound healing, and upregulation of E-selectin expression in the subject.

Priority: US2009-171271P Applic. Date: 2009-04-21; WO2010US30471 Applic. Date: 2010-04-09

Inventor: VELAZQUEZ OMAIDA C [US]; LIU ZHAO-JUN [US]


Application No.: US20120058934A1  Published: 08/Mar/2012

Title: TREATMENT OF DISEASES

Applicant/Assignee: DMI ACQUISITION CORP

Application No.: 13/227098   Filing Date: 07/Sep/2011

Abstract:

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification. The invention further provides a kit. The kit comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

Priority: US2010-380404P Applic. Date: 2010-09-07

Inventor: BAR-OR DAVID [US]


Application No.: US20120058952A1  Published: 08/Mar/2012

Title: HMG-COA REDUCTASE DERIVED PEPTIDE AND COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING SAME

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/141123   Filing Date: 23/Dec/2009

Abstract:

The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Priority: FR20080007362 Applic. Date: 2008-12-23; WO2009FR01475 Applic. Date: 2009-12-23

Inventor: FARRA CLAUDE DAL [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20120065131A1  Published: 15/Mar/2012

Title: COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE

Applicant/Assignee: REVANCE THERAPEUTICS, INC

Application No.: 13/220569   Filing Date: 29/Aug/2011

Abstract:

The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged "backbone" having positively charged branching or "efficiency" groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment. This invention also provides kits for preparing or formulating a composition that comprises the oligopeptide and optionally a carrier, as well as such additional items that are needed to produce a usable formulation, or a premix that may in turn be used to produce such a formulation.

Priority: US2005-658741P Applic. Date: 2005-03-03; US2006-368198 Applic. Date: 2006-03-03

Inventor: DAKE MICHAEL D [US]; WAUGH JACOB M [US]


Application No.: US20120065144A1  Published: 15/Mar/2012

Title: Peptide for the Prophylactic or Therapeutic Treatment of Skin Tumors in Initial Stages

Applicant/Assignee: ISDIN, S.A

Application No.: 13/255059   Filing Date: 04/Mar/2010

Abstract:

It comprises an inhibitor peptide of TGF-[beta]1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide.

Priority: WO2010ES70121 Applic. Date: 2010-03-04; ES20090000694 Applic. Date: 2009-03-06

Inventor: INSA BORONAT RAUL [ES]; QUINTANILLA AVILA MIGUEL [ES]; DOTOR DE LAS HERRERIAS JAVIER [ES]


Application No.: US20120070392A1  Published: 22/Mar/2012

Title: COMPOSITION FOR INHIBITING ERYTHEMA CAUSED BY ULTRAVIOLET RADIATION CONTAINING A DIPEPTIDE AS ACTIVE INGREDIENT

Applicant/Assignee:

Application No.: 13/258935   Filing Date: 30/Mar/2010

Abstract:

The present invention relates to a composition for inhibiting erythema caused by ultraviolet radiation, wherein said composition contains a specific dipeptide, selected from 400 dipeptides, as an active ingredient. The composition of the present invention inhibit the production of prostaglandin E2(PEG2), thereby inhibiting erythema caused by ultraviolet radiation.

Priority: KR20090027344 Applic. Date: 2009-03-31; WO2010KR01923 Applic. Date: 2010-03-30

Inventor: LEE HYUN-KYUNG [KR]; CHOI HYE-RYUNG [KR]; KANG YOUN-A [KR]


Application No.: US20120070399A1  Published: 22/Mar/2012

Title: ETHYLENE COPOLYMER WITH PEG, CATIONIC AND ANIONIC UNITS, COSMETIC COMPOSITION INCLUDING SAME AND TREATMENT METHOD

Applicant/Assignee: L'OREAL

Application No.: 13/260062   Filing Date: 11/Mar/2010

Abstract:

The present invention relates to novel ethylenic copolymers comprising: a) from 25 to 95% by weight of monomer of formula (I), comprising PEG units

b) from 4 to 50% by weight of cationic monomer or one of its salts

c) from 1 to 35% by weight of anionic monomer and/or its salts. The invention also relates to cosmetic compositions, in particular hair compositions, comprising said copolymers and to a cosmetic treatment method employing them.

Priority: US2009-169003P Applic. Date: 2009-04-14; WO2010FR50418 Applic. Date: 2010-03-11; FR20090052339 Applic. Date: 2009-04-09; FR20090003356 Applic. Date: 2009-07-08; FR20090056455 Applic. Date: 2009-09-21

Inventor: JEGOU GWENAELLE [FR]


Application No.: US20120071394A1  Published: 22/Mar/2012

Title: NOVEL POLYPEPTIDES AND USE THEREOF

Applicant/Assignee:

Application No.: 13/142835   Filing Date: 30/Nov/2009

Abstract:

The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus ('CHIPS'), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or variant retains amino acid substitutions K40E, D42V, N77H, K100R, K105R, N111 K and/or G112A relative to the wildtype CHIPS protein of SEQ ID NO:1. In one embodiment, polypeptide consists of the amino acid sequence of SEQ ID NO: 2. Related aspects of the invention provide pharmaceutical compositions comprising a polypeptide of the invention, together with methods or making and using the same.

Priority: GB20090005790 Applic. Date: 2009-04-03; US2009-193926P Applic. Date: 2009-01-08; WO2009GB02782 Applic. Date: 2009-11-30

Inventor: FUREBRING CHRISTINA [SE]; ROSEN ANNA [SE]; HARALDSSON KARIN [SE]; GUSTAFSSON ERIKA [SE]; WALSE BJOERN ULRIK [SE]


Application No.: US20120071414A1  Published: 22/Mar/2012

Title: METHOD FOR PRODUCING AND USING ACTIVE PRINCIPLES OF LIMESTONE

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS-, UNIVERSITE D'ORLEANS, MUSEUM NATIONAL D'HISTOIRE NATURELLE

Application No.: 13/262909   Filing Date: 09/Apr/2010

Abstract:

The present invention relates to a method for extracting organic molecules and/or organic minerals from a limestone material, including placing said limestone material in contact with a solution including at least one organic solvent, water and at least one acid, as well as to the organic molecules and/or organic minerals produced by the method. The products produced by the method can be used, for example, in therapeutic and non-therapeutic fields, in particular the agri-food, cosmetic and medical fields.

Priority: FR20090001804 Applic. Date: 2009-04-10; WO2010FR00298 Applic. Date: 2010-04-09

Inventor: BOURRAT XAVIER [FR]; LOPEZ EVELYNE [FR]; ROUSSEAU MARTHE [FR]


Application No.: US20120077731A1  Published: 29/Mar/2012

Title: AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS

Applicant/Assignee: ABLYNX N.V

Application No.: 13/263179   Filing Date: 12/Apr/2010

Abstract:

The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells, and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Priority: US2009-168410P Applic. Date: 2009-04-10; WO2010EP54764 Applic. Date: 2010-04-12

Inventor: BEIRNAERT ELS ANNA ALICE [BE]; VERVERKEN CEDRIC JOZEF NEOTERE [BE]; KOLKMAN JOOST ALEXANDER [NL]; VAN ROY MAARTEN [BE]


Application No.: US20120077732A1  Published: 29/Mar/2012

Title: CYCLIC PEPTIDES AND USES THEREOF

Applicant/Assignee: SYDNEY WEST AREA HEALTH SERVICE

Application No.: 13/130718   Filing Date: 24/Nov/2009

Abstract:

The present invention relates to cyclic peptides, comprising alternating D- and L- amino acids and wherein the peptide possesses immunomodulatory activity. The present invention also relates to pharmaceutical compositions comprising the cyclic peptides and to methods for the treatment of disease.

Priority: AU20080906085 Applic. Date: 2008-11-24; WO2009AU01530 Applic. Date: 2009-11-24

Inventor: MANOLIOS NICHOLAS [AU]; BENDER VERONIKA JUDIT [AU]; ALI MARINA [AU]


Application No.: US20120077733A1  Published: 29/Mar/2012

Title: ANTAGONISTS AGAINST INTERACTION OF PF4 AND RANTES

Applicant/Assignee: RWTH AACEHN

Application No.: 13/315088   Filing Date: 08/Dec/2011

Abstract:

The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment.

Priority: DE200510049637 Applic. Date: 2005-10-14; US2008-090010 Applic. Date: 2008-07-09; WO2006EP09790 Applic. Date: 2006-10-11

Inventor: WEBER CHRISTIAN [DE]; VON HUNDELSHAUSEN PHILIPP [DE]; KOENEN RORY [DE]


Application No.: US20120077750A1  Published: 29/Mar/2012

Title: USE OF A GROWTH-STIMULATING PROTEIN

Applicant/Assignee:

Application No.: 13/246696   Filing Date: 27/Sep/2011

Abstract:

This invention relates to the inhibition of a newly discovered growth-stimulating protein in an individual. Further, the invention relates to a method for preventing or treating a cancer, or preventing or treating cancer growth, invasion or metastasis, or preventing or treating other hyperproliferative diseases in an individual, by down regulating the expression of said growth-stimulating protein or by inactivating said protein. Still further, the invention concerns a method for diagnosing cancer or other hyperproliferative diseases in an individual based on said growth-stimulating protein.

Priority: FI20060000246 Applic. Date: 2006-03-16; US2008-225114 Applic. Date: 2008-12-02; WO2007FI50137 Applic. Date: 2007-03-14

Inventor: WESTERMARCK JUKKA [FI]; PUUSTINEN PIETRI [FI]; JUNTTILA MELISSA [US]


Application No.: US20120079614A1  Published: 29/Mar/2012

Title: CD109 POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF SKIN CELLS

Applicant/Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

Application No.: 13/148273   Filing Date: 19/Feb/2010

Abstract:

The invention concerns compounds, compositions and methods for the treatment of skin cells. Described herein are CD109 polypeptides and uses thereof for the in vivo treatment of various skin disorders, including skin fibrosis, skin scarring, wound healing and psoriasis.

Priority: US2009-150953P Applic. Date: 2009-02-09; WO2010CA00183 Applic. Date: 2010-02-09

Inventor: PHILIP ANIE [CA]; VORSTENBOSCH JOSHUA [CA]; LI CARTER [CA]; FINNSON KENNETH [CA]; SOE-LIN HAHN [US]; MAN XIAO-YONG [CA]; BIZET ALBANE [CA]; AL-AJMI HASAN [CA]


Application No.: US20120083445A1  Published: 05/Apr/2012

Title: Compositions Containing HC-HA Complex and Methods of Use Thereof

Applicant/Assignee: TISSUETECH, INC

Application No.: 13/262725   Filing Date: 26/Apr/2010

Abstract:

Disclosed herein, in certain embodiments, is an HC-HA complex comprising hyaluronan and a heavy chain of I[alpha]I, wherein the transfer of the heavy chain of I[alpha]I is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC-HA complex comprising hyaluronan and a heavy chain of I[alpha]I, wherein the transfer of the heavy chain of I[alpha]I is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof

Priority: US2009-172621P Applic. Date: 2009-04-24; US2009-267776P Applic. Date: 2009-12-08; WO2010US32452 Applic. Date: 2010-04-26

Inventor: TSENG SCHEFFER [US]; HE HUA [US]


Application No.: US20120088733A1  Published: 12/Apr/2012

Title: NOVEL USE OF ANTIMICROBIAL PEPTIDES IN REGENERATION OF SKIN CELLS

Applicant/Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Application No.: 13/095763   Filing Date: 27/Apr/2011

Abstract:

Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.

Priority: KR20100098259 Applic. Date: 2010-10-08; WO2010KR09558 Applic. Date: 2010-12-30

Inventor: KIM SUN-CHANG [KR]; KIM DA-JUNG [KR]; JANG SU-A [KR]; SUNG BONG HYUN [KR]; LIM KI-JUNG [KR]; SHIN JU-RI [KR]; LEE YOUNG WOONG [KR]


Application No.: US20120094920A1  Published: 19/Apr/2012

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDIC HYDROLYZATE THAT CAN REINFORCE THE BARRIER FUNCTION

Applicant/Assignee: ISP INVESTMENTS INC

Application No.: 13/264035   Filing Date: 15/Apr/2010

Abstract:

The invention relates to a peptidic hydrolyzate enriched in bioactive peptide, capable of reinforcing the skin barrier function and stimulating epidermal differentiation. The invention is also relative to a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, said hydrolyzate as active principle. The invention further relates to the use, in a cosmetic composition, of the active principle according to the invention to activate the HMG-CoA reductase in the cutaneous cells, and to prevent and combat the cutaneous signs of aging and photo-aging.

Priority: FR20090001822 Applic. Date: 2009-04-15; WO2010FR00311 Applic. Date: 2010-04-15

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20120094921A1  Published: 19/Apr/2012

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING A RELIEVING PEPTIDIC HYDROLYZATE

Applicant/Assignee:

Application No.: 13/264082   Filing Date: 15/Apr/2010

Abstract:

The invention concerns a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a peptide hydrolyzate which is enriched in soothing bioactive peptide. The invention also concerns the use, in a cosmetic composition, of the active principle in accordance with the invention to activate HMG-CoA reductase in skin cells and to prevent or combat skin irritations.

Priority: FR20090001824 Applic. Date: 2009-04-15; WO2010FR00312 Applic. Date: 2010-04-15

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20120100106A1  Published: 26/Apr/2012

Title: COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS FOR WOUND HEALING

Applicant/Assignee: PURDUE RESEARCH FOUNDATION

Application No.: 13/318710   Filing Date: 04/May/2010

Abstract:

Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient.

Priority: US2009-175200P Applic. Date: 2009-05-04; WO2010US33543 Applic. Date: 2010-05-04

Inventor: PANITCH ALYSSA [US]; PADERI JOHN E [US]


Application No.: US20120107410A1  Published: 03/May/2012

Title: PRODUCT FOR THE PREPARATION OF DERMATOLOGICAL, COSMETIC OR COSMECEUTICAL COMPOSITIONS INTENDED FOR SKIN TREATMENT

Applicant/Assignee: INDUSTRIAL FARMACEUTICA CANTABRIA, S.A

Application No.: 13/382912   Filing Date: 28/Jan/2010

Abstract:

The present invention relates to a product obtained from gastropod spawn, to be used to prepare dermatological, cosmetic or cosmeceutical compositions designed for skin care

said product has the capacity to activate and mobilise skin stem cells, as well as prevent the loss thereof that takes place as a consequence of chronological and premature ageing. The present invention also relates to the process followed in order to obtain said product.

Priority: WO2010ES00031 Applic. Date: 2010-01-28

Inventor: DOMINGUEZ VALDES-HEVIA MARTA [ES]; BRIEVA DELGADO AURORA [ES]; GONZALEZ RODRIGUEZ SALVADOR [ES]; REYES MARTIN EDUARDO [ES]; CARBALLEIRA MORADO JOSE [ES]; QUINTANA GONZALEZ ERNESTO [ES]; PIVEL RANIERI JUAN PABLO [ES]; GUERRERO GOMEZ-PAMO ANTONIO [ES]; JUARRANZ DE LA FUENTE ANGELES [ES]; ESPADA REGALADO JESUS [ES]; SANZ RODRIGUEZ FRANCISCO [ES]


Application No.: US20120107412A1  Published: 03/May/2012

Title: USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION

Applicant/Assignee: REGENICS AS

Application No.: 13/101445   Filing Date: 05/May/2011

Abstract:

The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.

Priority: US2009-437100 Applic. Date: 2009-05-07; US2007-801778 Applic. Date: 2007-05-11; US2010-332047P Applic. Date: 2010-05-06; US2008-051931P Applic. Date: 2008-05-09; US2008-120146P Applic. Date: 2008-12-05; US2006-799560P Applic. Date: 2006-05-11

Inventor: GAMMELSAETER RUNHILD [NO]; REMMEREIT JAN [NO]


Application No.: US20120114617A1  Published: 10/May/2012

Title: PEPTIDE PROMOTING CELL ADHESION AND MIGRATION

Applicant/Assignee: SYMATESE, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Application No.: 13/255299   Filing Date: 15/Mar/2010

Abstract:

Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.

Priority: FR20090001168 Applic. Date: 2009-03-13; WO2010FR50458 Applic. Date: 2010-03-15

Inventor: ROUSSELLE PATRICIA [FR]


Application No.: US20120114690A1  Published: 10/May/2012

Title: EXTERNAL USE COMPOSITION FOR SKIN

Applicant/Assignee:

Application No.: 13/289648   Filing Date: 04/Nov/2011

Abstract:

The present disclosure provides an external use composition for skin comprising a tarajo holly leaf extract and a Japanese knotweed leaf extract, a brown algae extract and an egg shell membrane derived peptide (ESM-P) having a molecular mass of 3 kDa or higher. The composition according to the present invention can be used to treat a disease or condition of skin relating to a filaggrin metabolism anomaly, such as atopic dermatitis. The composition according to the present invention can be used specifically for the therapy of atopic dermatitis.

Priority: JP20100247525 Applic. Date: 2010-11-04

Inventor: OHISHI HIFUMI [JP]; OHISHI KEIZOU [JP]; OISHI TETSUYA [JP]; TANI HISANORI [JP]


Application No.: US20120114703A1  Published: 10/May/2012

Title: Botulinum Toxin Administration to Treat Various Conditions

Applicant/Assignee: ALLERGAN, INC

Application No.: 13/212962   Filing Date: 18/Aug/2011

Abstract:

Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.

Priority: US2008-340150 Applic. Date: 2008-12-19; US2006-538503 Applic. Date: 2006-10-04; US2002-051952 Applic. Date: 2002-01-17; US2000-730237 Applic. Date: 2000-12-05

Inventor: WALKER PATRICIA S [US]


Application No.: US20120115773A1  Published: 10/May/2012

Title: MODIFIED OMCI AS A COMPLEMENT INHIBITOR

Applicant/Assignee: NATURAL ENVIRONMENT RESEARCH COUNCIL

Application No.: 13/148045   Filing Date: 04/Feb/2010

Abstract:

The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK/E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement.

Priority: WO2010GB00213 Applic. Date: 2010-02-04; WO2009GB00311 Applic. Date: 2009-02-05; GB20090006779 Applic. Date: 2009-04-20

Inventor: NUNN MILES A [GB]; LEA SUSAN M [GB]; ROVERSI PIETRO [GB]


Application No.: US20120121521A1  Published: 17/May/2012

Title: Cosmetic coating to protect unclothed skin from thermal injury

Applicant/Assignee: TEXAS RESEARCH INTERNATIONAL, INC

Application No.: 13/066845   Filing Date: 26/Apr/2011

Abstract:

A hydrogel composition and a method for protecting a surface from thermal injury is disclosed. The method comprises applying a hydrogel composition to the surface to protect the skin from exposure to a heat flux, wherein the hydrogel is of a type and applied in an amount effective to reduce heat flux by at least 40 percent when exposed to a heat flux of 40 kW/m2. Representative examples of such hydrogels include ionized carboxymethyl cellulose hydrogel, ionized polyacrylate hydrogel, and a polymer formed from acrylic acid and crosslinked with polyalkenyl ethers or divinyl glycol.

Priority: US2010-343253P Applic. Date: 2010-04-26

Inventor: BULLUCK JOHN W [US]


Application No.: US20120121572A1  Published: 17/May/2012

Title: NEW MEDICINES FOR TOPIC USE BASED ON SULFATED HYALURONIC ACID AS ACTIVATING OR INHIBITING AGENT OF THE CYTOKINE ACTIVITY

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 13/320000   Filing Date: 14/May/2010

Abstract:

The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.

Priority: IT2009PD00134 Applic. Date: 2009-05-14; WO2010EP03050 Applic. Date: 2010-05-14

Inventor: D ESTE MATTEO [IT]; GENNARI GIOVANNI [IT]


Application No.: US20120121591A1  Published: 17/May/2012

Title: SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3

Applicant/Assignee: AMGEN INC

Application No.: 13/258454   Filing Date: 19/Mar/2010

Abstract:

Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.

Priority: US2009-210594P Applic. Date: 2009-03-20; WO2010US28061 Applic. Date: 2010-03-19

Inventor: SULLIVAN JOHN K [US]; MIRANDA LESLIE P [US]; GEGG COLIN V [US]; HU SHAW-FEN SYLVIA [US]; BELOUSKI EDWARD J [US]; MURRAY JUSTIN K [US]; NGUYEN HUNG [US]; WALKER KENNETH W [US]; ARORA TARUNA [US]; JACOBSEN FREDERICK W [US]; LI YUE-SHENG [US]; BOONE THOMAS C [US]


Application No.: US20120121686A1  Published: 17/May/2012

Title: BIODEGRADABLE COMPOSITIONS HAVING PRESSURE SENSITIVE ADHESIVE PROPERTIES

Applicant/Assignee: COHERA MEDICAL, INC

Application No.: 13/296670   Filing Date: 15/Nov/2011

Abstract:

A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2

and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22 DEG C. and below, and has pressure sensitive adhesive properties at a temperature of 37 DEG C. and relative humidity of 100%. The composition may be used to adhere polymer meshes or films to biological tissue.

Priority: US2010-413546P Applic. Date: 2010-11-15

Inventor: BECKMAN ERIC J [US]; MEYERS JESSICA L [US]


Application No.: US20120121724A1  Published: 17/May/2012

Title: FILM COMPRISING THERAPEUTIC AGENTS

Applicant/Assignee:

Application No.: 13/355414   Filing Date: 20/Jan/2012

Abstract:

The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.

Priority: US2003-497426P Applic. Date: 2003-08-21; US2003-484009P Applic. Date: 2003-07-01; WO2004US21038 Applic. Date: 2004-06-30; US2004-562633 Applic. Date: 2004-06-30

Inventor: MAIBACH TODD [US]


Application No.: US20120121725A1  Published: 17/May/2012

Title: COSMETIC COMPOSITION FOR THE TREATMENT OF ACNE COMPRISING A PEPTIDE EXTRACT OF SCHIZANDRA

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: 13/387518   Filing Date: 27/Jul/2010

Abstract:

The present invention relates to a cosmetic, nutraceutical or dermatological composition for treating or preventing acne, comprising a peptide and oside extract of Schizandra fruit and a suitable excipient. Preferably, the extract is obtained from Schizandra sphenanthera. The composition may also comprise at least one anti-acne agent selected from a sebum-regulating agent, an antibacterial and/or antifungal agent, a keratolytic agent and/or a keratoregulating agent, an astringent, an anti-inflammatory and/or anti-irritant, an antioxidant and/or a free-radical scavenger, a cicatrizing agent, an anti-ageing agent and a moisturizing agent. The invention also relates to a method for cosmetic treatment of acne, characterized in that a cosmetic composition according to the invention is applied to the affected areas of the skin, or in that the affected individual takes a nutraceutical composition according to the invention orally.

Priority: FR20090055343 Applic. Date: 2009-07-30; WO2010EP60876 Applic. Date: 2010-07-27

Inventor: GARNIER SEBASTIEN [FR]; NAAIMI DALALE [FR]; BAUDOUIN CAROLINE [FR]


Application No.: US20120122763A1  Published: 17/May/2012

Title: NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS

Applicant/Assignee: AETERNA ZENTARIS GMBH

Application No.: 13/358055   Filing Date: 25/Jan/2012

Abstract:

The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.

Priority: EP20070107094 Applic. Date: 2007-04-27; US2008-109479 Applic. Date: 2008-04-25; US2007-914424P Applic. Date: 2007-04-27

Inventor: SCHUSTER TILMANN [DE]; PAULINI KLAUS [DE]; SCHMIDT PETER [DE]; BAASNER SILKE [DE]; POLYMEROPOULOS EMMANUEL [DE]; GUENTHER ECKHARD [DE]; TEIFEL MICHAEL [DE]


Application No.: US20120129776A1  Published: 24/May/2012

Title: Bioactive peptides and method of using same

Applicant/Assignee:

Application No.: 11/901939   Filing Date: 18/Sep/2007

Abstract:

Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.

Priority: US2006-845606P Applic. Date: 2006-09-18; US2006-846421P Applic. Date: 2006-09-21; US2006-851591P Applic. Date: 2006-10-12

Inventor: COHEN YOSSI [IL]; SHEMESH RONEN [IL]; TOPORIK AMIR [IL]; LEVINE ZURIT [IL]; WOOL ASSAF [IL]; DAHARY DVIR [IL]; HECHT IRIS [IL]; BEIMAN MERAV [IL]; ROTMAN GALIT [IL]; AYALON-SOFFER MICHAL [IL]


Application No.: US20120129784A1  Published: 24/May/2012

Title: Oligopeptides And Cosmetic Compositions Containing The Oligopeptides

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 13/328684   Filing Date: 16/Dec/2011

Abstract:

Oligopeptides according to formula (I) and/or (II), R1-Tyr-Pro-Trp-Phe-NH2 (I, SEQ ID NO:1)

R1-Tyr-Pro-PhePhe-NH2 (II, SEQ ID NO:2), wherein R1 is linked to the NH2-group of the amino-terminal part of Tyr and is selected from the group consisting of -H

a linear saturated or unsaturated or branched saturated or unsaturated acyl group having 1 to 24 carbon atoms, which may be functionalized by a -OH, -SH, -COOH or -CONH+ group

a sterol or a sphingolipid group which is linked to the amino terminal part of Tyr via a bifunctional linker are disclosed. Cosmetic compositions containing the oligopeptides are also disclosed.

Priority: EP20050023954 Applic. Date: 2005-11-03; WO2006EP10258 Applic. Date: 2006-10-25; US2008-092476 Applic. Date: 2008-05-02

Inventor: GILLON VERONIQUE [FR]; MOUSSOU PHILIPPE [FR]; CONTET-AUDONNEAU JEAN-LUC [FR]; FREIS OLGA [FR]


Application No.: US20120129785A1  Published: 24/May/2012

Title: COMPANION ANIMAL NUTRITION SYSTEM

Applicant/Assignee: HILL'S PET NUTRITION, INC

Application No.: 13/384778   Filing Date: 21/Jul/2010

Abstract:

The invention encompasses a nutrition system for a companion animal that includes a plurality of pet food packets, wherein an amount of pet food corresponding to a single meal for a companion animal may be selected and wherein the amount of pet food is formulated to alleviate or manage a disorder in a companion animal. In various embodiments, the pet food packets include the nutritional requirements for a companion animal (e.g., protein, fiber, fat) as well as one or more ingredients that alleviate or manage a disorder in a companion animal.

Priority: WO2010US42681 Applic. Date: 2010-07-21; US2009-227197P Applic. Date: 2009-07-21; US2009-231175P Applic. Date: 2009-08-04

Inventor: FLEURANGES LESLIE [US]; TOLSDORF GEOFFREY [US]


Application No.: US20120134942A1  Published: 31/May/2012

Title: Hybrid copolymer compositions for personal care applications

Applicant/Assignee: AKZO NOBEL N.V

Application No.: 13/387906   Filing Date: 30/Jul/2010

Abstract:

A personal care composition includes a hybrid copolymer including at least one ethylenically unsaturated monomer and a naturally derived hydroxyl containing chain transfer agent as an end group, a hybrid synthetic copolymer including one or more synthetic polymers derived from the at least one ethylenically unsaturated monomer with at least one initiator fragment as an end group and an effective amount of a cosmetic or personal care additive.

Priority: US2009-533802 Applic. Date: 2009-07-31; US2010-689844 Applic. Date: 2010-01-19; WO2010US43949 Applic. Date: 2010-07-30; EP20090175465 Applic. Date: 2009-11-10

Inventor: THOMAIDES JOHN S [US]; RODRIGUES KLIN A [US]; VONA JR SAMUEL A [US]; MARTINO GARY T [US]; ADAMO ANTHONY J [US]


Application No.: US20120134950A1  Published: 31/May/2012

Title: Adhesion-Promoting thin Film and Moisture Resistant Skin Barrier Compositions

Applicant/Assignee:

Application No.: 13/284053   Filing Date: 28/Oct/2011

Abstract:

Adhesion-promoting, thin film, moisture resistant skin barrier formulations are composed of a fugitive solvent mixture consisting of t-butanol and an alkane fraction composed of at least one alkane, where the t-butanol is in the range of 40-70% by weight of the solvent mixture, and a film-forming solute dissolved in the fugitive solvent mixture. The formulations may also include one or more optional ingredients such as antimicrobial and/or bioactive agents. When applied to the skin, the formulations improve the adhesion of various classes of medical adhesives used to attach a variety of medical devices to the skin and create a thin, flexible and elastic continuous barrier film on the skin to protect against body fluids and incontinence.

Priority: US2010-407533P Applic. Date: 2010-10-28

Inventor: BABB STEVEN J [US]; KAY DENNIS M [US]


Application No.: US20120135916A1  Published: 31/May/2012

Title: MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE

Applicant/Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC

Application No.: 13/265968   Filing Date: 13/Apr/2010

Abstract:

Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

Priority: US2009-171979P Applic. Date: 2009-04-23; WO2010US30836 Applic. Date: 2010-04-13

Inventor: PUGIA MICHAEL J [US]; MA RUI [US]


Application No.: US20120135937A1  Published: 31/May/2012

Title: INJECTABLE COMBINATION OF ADRENERGIC RECEPTOR AGONISTS WITH FILLERS, FOR DECREASING SKIN REACTIONS DUE TO INJECTION

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, SYMATESE

Application No.: 13/322803   Filing Date: 28/May/2010

Abstract:

The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.

Priority: US2009-213322P Applic. Date: 2009-05-29; WO2010EP57493 Applic. Date: 2010-05-28

Inventor: BERTHOLON ISABELLE [FR]; BRUNEL FLORENCE [FR]; HERBAGE BENJAMIN [FR]; VILLARD CHRISTOPHE [FR]; VILLARD SYLVIANE [FR]


Application No.: US20120141416A1  Published: 07/Jun/2012

Title: MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF

Applicant/Assignee: ANGIOCHEM INC

Application No.: 13/382069   Filing Date: 30/Jun/2010

Abstract:

The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.

Priority: WO2010CA01014 Applic. Date: 2010-06-30; US2009-222785P Applic. Date: 2009-07-02; US2009-252024P Applic. Date: 2009-10-15

Inventor: DEMEULE MICHEL [CA]; CHE CHRISTIAN [CA]; THIOT CARINE [CA]


Application No.: US20120141483A1  Published: 07/Jun/2012

Title: METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES

Applicant/Assignee:

Application No.: 13/375878   Filing Date: 03/Jun/2010

Abstract:

The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of psoriasis and/or Alzheimer's diseases using the same.

Priority: US2009-184157P Applic. Date: 2009-06-04; WO2010US37227 Applic. Date: 2010-06-03

Inventor: DELMEDICO MARY KATHERINE [US]


Application No.: US20120141538A1  Published: 07/Jun/2012

Title: MODULATORS OF THE CX3CRI RECEPTOR AND THERAPEUTIC USES THEREOF

Applicant/Assignee: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VI

Application No.: 13/140615   Filing Date: 16/Dec/2009

Abstract:

The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.

Priority: WO2008IB55683 Applic. Date: 2008-12-17; WO2009EP67325 Applic. Date: 2009-12-16

Inventor: GOROCHOV GUY [FR]; DORGHAM KARIM [FR]; COMBADIERE CHRISTOPHE [FR]; DETERRE PHILIPPE [FR]


Application No.: US20120142595A1  Published: 07/Jun/2012

Title: TISSUE PROTECTIVE PEPTIDES AND USES THEREOF

Applicant/Assignee: ARAIM PHARMACEUTICALS, INC

Application No.: 13/278131   Filing Date: 20/Oct/2011

Abstract:

Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO

methods for treating or preventing a disease or disorder using tissue protective peptides

and methods for enhancing excitable tissue function using tissue protective peptides.

Priority: US2008-997898 Applic. Date: 2008-10-29; WO2006US31061 Applic. Date: 2006-08-07; US2005-705741P Applic. Date: 2005-08-05; US2005-706276P Applic. Date: 2005-08-08; US2006-831737P Applic. Date: 2006-07-18

Inventor: CERAMI ANTHONY [US]; BRINES MICHAEL [US]; COLEMAN THOMAS [US]


Application No.: US20120142605A1  Published: 07/Jun/2012

Title: METHODS OF TREATING PSORIASIS

Applicant/Assignee: AMGEN INC

Application No.: 13/319004   Filing Date: 05/May/2010

Abstract:

The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.

Priority: US2009-175748P Applic. Date: 2009-05-05; WO2010US33775 Applic. Date: 2010-05-05

Inventor: HOOPER MICHELE M [US]; THOMPSON ELIZABETH H Z [US]


Application No.: US20120156148A1  Published: 21/Jun/2012

Title: Pituitous Silicone Fluids

Applicant/Assignee:

Application No.: 13/392573   Filing Date: 01/Sep/2010

Abstract:

Personal care compositions containing pituitous silicone fluids compositions are disclosed. The silicone fluid compositions contain certain branched and/or high molecular weight organopolysiloxanes that demonstrate pituitous rheological behavior. When formulated into personal care compositions, the silicone fluids provide enhanced sensory and film-forming properties based on their pituitous rheological properties.

Priority: US2009-239529P Applic. Date: 2009-09-03; WO2010US47471 Applic. Date: 2010-09-01

Inventor: SHIKANO NAOKI [JP]; STARCH MICHAEL STEPHEN [US]; VANDORT PAUL CORNELIUS [US]


Application No.: US20120156163A1  Published: 21/Jun/2012

Title: METHODS OF DECREASING SEBUM PRODUCTION IN THE SKIN

Applicant/Assignee:

Application No.: 13/325826   Filing Date: 14/Dec/2011

Abstract:

Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject. In some embodiments, the nitric oxide source includes small molecule and/or macromolecular NO-releasing compounds.

Priority: US2010-423292P Applic. Date: 2010-12-15; US201161504634P Applic. Date: 2011-07-05

Inventor: BAUMAN SUSANNE [US]; STASKO NATHAN A [US]


Application No.: US20120157387A1  Published: 21/Jun/2012

Title: ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN

Applicant/Assignee: APOTEX TECHNOLOGIES INC

Application No.: 13/400351   Filing Date: 20/Feb/2012

Abstract:

Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds.

Priority: CA20062569204 Applic. Date: 2006-11-28; US2009-515217 Applic. Date: 2009-05-15; WO2007CA02123 Applic. Date: 2007-11-26

Inventor: TAM TIM FAT [CA]; LEUNG-TOUNG REGIS [CA]; WANG YINGSHENG [CA]; ZHAO YANQING [CA]; XIN TAO [CA]; LI WANREN [CA]; WODZINSKA JOLANTA MARIA [CA]; RABADIA VRAJLAL S [CA]; SHAH BIRENKUMAR [CA]; FEENEY CHRISTOPHER JOHN [CA]


Application No.: US20120172287A1  Published: 05/Jul/2012

Title: Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide

Applicant/Assignee: ANGES MG, INC

Application No.: 13/322424   Filing Date: 25/May/2010

Abstract:

A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.

Priority: JP20090125072 Applic. Date: 2009-05-25; WO2010JP58838 Applic. Date: 2010-05-25

Inventor: GEMBA TAKEFUMI [JP]; TOMIOKA HIDEKI [JP]; TAMURA NAO [JP]; SATA RYOKO [JP]; MAEDA AKITO [JP]; TENMA AKIKO [JP]; KANAMORI TOSHIHIDE [JP]; SAITO YOSHIMI [JP]; KOMABA SHINTARO [JP]; MORISHITA RYUICHI [JP]


Application No.: US20120172309A1  Published: 05/Jul/2012

Title: TRANSGLUTAMINASE-ACTIVATING PEPTIDE AND COSMETIC OR PHARMACEUTIAL COMPOSITION CONTAINING SAME

Applicant/Assignee:

Application No.: 13/394043   Filing Date: 31/Aug/2010

Abstract:

The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2. The present invention also relates to a cosmetic or pharmaceutical composition, containing at least one peptide of general formula (I), in a physiologically suitable medium. The present invention also relates to the use of a composition containing the peptide of general formula (I) as an active ingredient which activates human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing and/or for combatting external stresses and signs of skin ageing.

Priority: WO2010FR00595 Applic. Date: 2010-08-31; FR20090004218 Applic. Date: 2009-09-04

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20120178697A9  Published: 12/Jul/2012

Title: Compositions and methods for the inhibition of dishevelled proteins

Applicant/Assignee:

Application No.: 11/097518   Filing Date: 01/Apr/2005

Abstract:

The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.

Priority: US2004-849067 Applic. Date: 2004-05-19; US2003-504860P Applic. Date: 2003-09-22; US2005-084668 Applic. Date: 2005-03-18

Inventor: ZHENG JIE [US]; SHAN JUFANG [US]; WU DIANQING [US]


Application No.: US20120183538A1  Published: 19/Jul/2012

Title: SPARC ANTISENSE COMPOSITIONS AND USES THEREOF

Applicant/Assignee: ABRAXIS BIOSCIENCE, LLC

Application No.: 13/382803   Filing Date: 09/Jul/2010

Abstract:

The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.

Priority: WO2010US41600 Applic. Date: 2010-07-09; US2009-224431P Applic. Date: 2009-07-09

Inventor: TRIEU VUONG [US]; HWANG LARN [US]; DESAI NEIL [US]


Application No.: US20120183541A1  Published: 19/Jul/2012

Title: HAIR GROWTH METHODS USING FGFR4 EXTRACELLULAR DOMAINS

Applicant/Assignee:

Application No.: 13/496182   Filing Date: 15/Sep/2010

Abstract:

The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.

Priority: US2009-242754P Applic. Date: 2009-09-15; US2009-288190P Applic. Date: 2009-12-18; WO2010US48957 Applic. Date: 2010-09-15

Inventor: BRENNAN THOMAS [US]; DEAN ROBERT [US]; KAVANAUGH W MICHAEL [US]; POWERS JANINE [US]


Application No.: US20120184493A1  Published: 19/Jul/2012

Title: DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS

Applicant/Assignee: PANMIRA PHARMACEEUTICALS, LLC

Application No.: 13/387047   Filing Date: 28/Jul/2010

Abstract:

Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP2 receptor antagonist compound formulated for dermal administration

Priority: US2009-230585P Applic. Date: 2009-07-31; WO2010US43599 Applic. Date: 2010-07-28

Inventor: HUTCHINSON JOHN HOWARD [US]


Application No.: US20120196789A1  Published: 02/Aug/2012

Title: PEPTIDE BASED PEROXIDASE INHIBITORS AND METHODS OF USING SAME

Applicant/Assignee:

Application No.: 13/500040   Filing Date: 05/Oct/2010

Abstract:

The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.

Priority: US2009-248627P Applic. Date: 2009-10-05; WO2010US51425 Applic. Date: 2010-10-05

Inventor: ZHANG HAO [US]; SHI YANG [US]; XU HAO [US]; PRITCHARD JR KIRKWOOD A [US]


Application No.: US20120196790A1  Published: 02/Aug/2012

Title: CYCLIC DEPSIPEPTIDES

Applicant/Assignee: NOVARTIS AG

Application No.: 13/372758   Filing Date: 14/Feb/2012

Abstract:

The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.

Priority: EP20070114507 Applic. Date: 2007-08-17; US2008-193338 Applic. Date: 2008-08-18

Inventor: KRASTEL PHILIPP [DE]; LIECHTY BRIGITTA-MARIA [CH]; MEINGASSNER JOSEF GOTTFRIED [AT]; SCHMITT ESTHER [DE]; SCHREINER ERWIN PAUL [AT]


Application No.: US20120202733A1  Published: 09/Aug/2012

Title: INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS

Applicant/Assignee: SIGNABLOK, INC

Application No.: 13/501992   Filing Date: 13/Oct/2010

Abstract:

Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

Priority: US2009-251283P Applic. Date: 2009-10-13; WO2010US52566 Applic. Date: 2010-10-13

Inventor: SIGALOV ALEXANDER B [US]


Application No.: US20120207812A1  Published: 16/Aug/2012

Title: SKINCARE COMPOSITIONS COMPRISING SALICYCLIC ACID

Applicant/Assignee: RECKITT & COLMAN (OVERSEAS) LIMITED

Application No.: 13/453167   Filing Date: 23/Apr/2012

Abstract:

There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises salicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatment of acne.

Priority: GB20040003702 Applic. Date: 2004-02-19; GB20040019260 Applic. Date: 2004-08-31; US2009-537514 Applic. Date: 2009-08-07; US2005-590061 Applic. Date: 2005-02-19; WO2005GB00503 Applic. Date: 2005-02-19

Inventor: STRODTHOLZ IRIS [DE]; SCHMIDT TIMM [DE]; STRAHINJIC IVANA [DE]


Application No.: US20120213727A1  Published: 23/Aug/2012

Title: THERAPEUTIC USES OF OLIGOMERIC AND POLYMERIC MONOTERPENES

Applicant/Assignee: REGENERA PHARMA LTD

Application No.: 13/503463   Filing Date: 28/Oct/2010

Abstract:

The invention relates to therapeutic methods comprising use of oligomeric and polymeric forms of the monoterpene compounds alloocimene, limonene, alpha-pinene, beta-pinene, geranyl acetate, alpha-phellandrene, gamma-terpinene, 3-carene and 2-carene. More particularly, the invention relates to methods of treating degenerative neurological conditions, and treating skin disorders.

Priority: WO2010IL00893 Applic. Date: 2010-10-28; US2009-272737P Applic. Date: 2009-10-28

Inventor: HAZAN ZADIK [IL]


Application No.: US20120213843A1  Published: 23/Aug/2012

Title: COMPOSITION FOR PROMOTING WOUND HEALING

Applicant/Assignee: LIPIDOR AB

Application No.: 13/505502   Filing Date: 03/Nov/2010

Abstract:

A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a wound healing agent, in particular a low to medium size natural or synthetic peptide. Also disclosed is a method of forming the lipid layer on a wound and a medical patch provided with the composition.

Priority: WO2010SE00269 Applic. Date: 2010-11-03; SE20090001408 Applic. Date: 2009-11-03; SE20100000022 Applic. Date: 2010-01-12

Inventor: CARLSSON ANDERS [SE]; HOLMBACK JAN [SE]


Application No.: US20120214731A1  Published: 23/Aug/2012

Title: COMPOUND WS 727713

Applicant/Assignee: ASTELLAS PHARMA, INC

Application No.: 13/354308   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.

Priority: AU20040901919 Applic. Date: 2004-04-08; US2010-757684 Applic. Date: 2010-04-09; US2006-547729 Applic. Date: 2006-10-06; WO2005JP05653 Applic. Date: 2005-03-22

Inventor: OTSUKA TAKANAO [JP]; UEDA HIROTSUGU [JP]; FUJIE KEIKO [JP]; MURAMATSU HIDEYUKI [JP]; HASHIMOTO MICHIZANE [JP]; TAKASE SHIGEHIRO [JP]


Application No.: US20120214743A1  Published: 23/Aug/2012

Title: ITCH SUPPRESSANT

Applicant/Assignee: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN

Application No.: 13/503153   Filing Date: 22/Oct/2010

Abstract:

The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. [SEQ: ID No. 1] Val-Ser-Gln-Arg-Thr-Asp-Gly-Glu-Ser-Arg-Ala-His- Leu-Gly-Ala-Leu-Leu-Ala-Arg-Tyr-Ile-Gln-Gln-Ala- Arg-Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys- Asn-Leu-Gln-Asn-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser- Asp-Arg-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Priority: JP20090244528 Applic. Date: 2009-10-23; WO2010JP68695 Applic. Date: 2010-10-22

Inventor: TOKURA YOSHIKI [JP]; FUKAMACHI SHOKO [JP]


Application No.: US20120219536A1  Published: 30/Aug/2012

Title: PURINE-TARGETED DIAGNOSIS AND THERAPY OF WOUNDS

Applicant/Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY

Application No.: 13/392340   Filing Date: 13/Aug/2010

Abstract:

Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid

(ii) a level of one or more uric acid precursors

and (iii) a presence, or absence of or level of xanthine oxidoreductase.

Priority: AU20090904013 Applic. Date: 2009-08-24; WO2010AU01037 Applic. Date: 2010-08-13

Inventor: FERNANDEZ MELISSA LAURA [AU]; SHOOTER GARY KEITH [AU]


Application No.: US20120219544A1  Published: 30/Aug/2012

Title: ADHESIVE COMPOSITION FOR SOFT TISSUES, ADHESIVE COMPOSITION FOR WOUND DRESSING OR WOUND DRESSING COMPOSITION

Applicant/Assignee: MITSUI CHEMICALS, INC

Application No.: 13/508009   Filing Date: 18/Nov/2010

Abstract:

The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties.

Priority: JP20090265649 Applic. Date: 2009-11-20; WO2010JP70546 Applic. Date: 2010-11-18; JP20090265647 Applic. Date: 2009-11-20

Inventor: ASADA NORIAKI [JP]; AOKI SHINYA [JP]; NARUSE HIROSHI [JP]; MIYAKOSHI SHOICHI [JP]; ARATA MASAMI [JP]


Application No.: US20120219574A1  Published: 30/Aug/2012

Title: ANTIGEN SURROGATES IN AUTOIMMUNE DISEASE

Applicant/Assignee: OPKO PHARMACEUTICALS, LLC

Application No.: 13/443536   Filing Date: 10/Apr/2012

Abstract:

The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.

Priority: WO2012US20660 Applic. Date: 2012-01-09; US201161431328P Applic. Date: 2011-01-10

Inventor: FROST PHILLIP [US]; KODADEK THOMAS [US]


Application No.: US20120220536A1  Published: 30/Aug/2012

Title: USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS

Applicant/Assignee:

Application No.: 13/503339   Filing Date: 22/Oct/2010

Abstract:

C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4

(2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4

or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions

wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.

Priority: US2009-254143P Applic. Date: 2009-10-22; US2009-261280P Applic. Date: 2009-11-13; WO2010US53831 Applic. Date: 2010-10-22

Inventor: FEGHALI-BOSTWICK CAROL A [US]; YAMAGUCHI YUKIE [US]


Application No.: US20120225107A1  Published: 06/Sep/2012

Title: STABLE SKIN AND SCAR TREATMENT COMPOSITION

Applicant/Assignee:

Application No.: 13/410745   Filing Date: 02/Mar/2012

Abstract:

Provided are dermatological compositions for skin and scar treatment, methods of making the compositions and methods of applying the compositions, which result in improved skin and scar whitening performance. In one form, the dermatological composition for skin and scar treatment includes 33 to 60 wt. % of one or more hydrophilic benefiting ingredients, and 40 to 60 wt. % of an anhydrous hydrophilic/amphiphatic base comprising 1 to 35 wt. % of propylene glycol, 1 to 15 wt. % of polyethylene glycol, 1 to 20 wt. % of cetyl alcohol, 1 to 20 wt. % stearyl alcohol, 1 to 10 wt. % of ethoxydiglycol, 0.1 to 2.0 wt. % of dexapanthenol, 0.1 to 1.0 wt. % of phenoxyethanol, and 0.1 to 2.0 wt. % of tocophersolan (TPGS). The one or more hydrophilic benefiting ingredients may include skin whitening agents, antioxidants, extracts, antifungal/antibacterial/anti-acne agents, polypeptides, anti-inflammatory agents, keratolytic agents, amino acids and combinations thereof.

Priority: US201161449447P Applic. Date: 2011-03-04

Inventor: HECHAVARRIA CARIDAD [US]


Application No.: US20120231994A1  Published: 13/Sep/2012

Title: ANTAGONISM OF HUMAN FORMYL PEPTIDE RECEPTOR FOR TREATMENT OF DISEASE

Applicant/Assignee: NIKAN PHARMACEUTICALS, LLC

Application No.: 13/375599   Filing Date: 02/Jun/2010

Abstract:

The present invention is directed to modulators of eosinophilic and neutrophilic function and the use of such modulators for treatment of eosinophil-associated and neutrophil-associated diseases.

Priority: US2009-183368P Applic. Date: 2009-06-02; US2009-183375P Applic. Date: 2009-06-02; US2009-183358P Applic. Date: 2009-06-02; US2009-227642P Applic. Date: 2009-07-22; US2009-227657P Applic. Date: 2009-07-22; US2009-227643P Applic. Date: 2009-07-22; WO2010US37068 Applic. Date: 2010-06-02

Inventor: BENSON JOHN D [US]


Application No.: US20120237458A1  Published: 20/Sep/2012

Title: HYDROGEL PARTICLES

Applicant/Assignee:

Application No.: 13/513545   Filing Date: 30/Nov/2010

Abstract:

Hydrogel particles include: (A) a water-insoluble complex containing catechins

(B) a compound which forms chelate together with divalent or trivalent metal ions

(C) a divalent or trivalent metal salt

(D) a gel-forming agent

and (E) water.

Priority: JP20090276727 Applic. Date: 2009-12-04; WO2010JP06985 Applic. Date: 2010-11-30

Inventor: SHIDAHARA YASUHIRO [JP]; TAKAGI MICHIYA [JP]; FUKUDA KIMIKAZU [JP]; NAKATSU SUSUMU [JP]; ICHIMURA IKUHISA [JP]; TOKUNAGA TADAYUKI [JP]


Application No.: US20120237624A1  Published: 20/Sep/2012

Title: VIGNA UNGUICULATA SEED EXTRACT AND COMPOSITIONS CONTAINING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: 13/512581   Filing Date: 30/Nov/2010

Abstract:

The invention relates to a composition comprising a Vigna unguiculata seed extract. The composition is advantageously cosmetic, pharmaceutical, dermatological or nutraceutical. The invention further relates to a method for extracting a Vigna unguiculata seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders or pathologies of the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders, or for use in the prevention or treatment of adipose tissue alterations. Finally, the invention relates to a method for cosmetic care of the skin, appendages or mucosae, in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.

Priority: FR20090058529 Applic. Date: 2009-11-30; WO2010EP68573 Applic. Date: 2010-11-30

Inventor: MSIKA PHILIPPE [FR]; SAUNOIS ALEX [FR]; LECLERE-BIENFAIT SOPHIE [FR]; BAUDOIN CAROLINE [FR]


Application No.: US20120238500A1  Published: 20/Sep/2012

Title: REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO

Applicant/Assignee: CURIS, INC

Application No.: 13/330631   Filing Date: 19/Dec/2011

Abstract:

The present application is directed to the discovery that preparations of hedgehog polypeptides can be used to control the formation and/or maintenance of epithelial tissue.

Priority: US2008-217329 Applic. Date: 2008-07-03; US2005-182691 Applic. Date: 2005-07-15; US2001-827110 Applic. Date: 2001-04-05; US1998-151999 Applic. Date: 1998-09-11; US1997-955552 Applic. Date: 1997-10-20

Inventor: WANG ELIZABETH A [US]


Application No.: US20120238503A1  Published: 20/Sep/2012

Title: HUMAN LAMININ ALPHA2 CHAIN LG3 DOMAIN AND ACTIVE PEPTIDES PROMOTING CELL ADHESION, SPREADING, MIGRATION, AND NEURITE OUTGROWTH

Applicant/Assignee: SNU R&DB FOUNDATION

Application No.: 13/418137   Filing Date: 12/Mar/2012

Abstract:

The present invention relates to human laminin [alpha]2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin [alpha]2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC[delta] and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.

Priority: KR20110022946 Applic. Date: 2011-03-15

Inventor: MIN BYUNG-MOO [KR]


Application No.: US20120238505A1  Published: 20/Sep/2012

Title: Medicaments

Applicant/Assignee: RENOVO LIMITED

Application No.: 13/317030   Filing Date: 07/Oct/2011

Abstract:

The present invention relates to the use of a peptide, or derivative thereof of general formula X1-X2-X3-ThT-X4-LyS-X5-ATg-X6 for promoting accelerated wound healing with reduced scarring. X1 is Ala or Gly

X2 is Tyr or Phe

X3, X4 and X5 are independently selected from the group comprising Met, He, Leu and Val

and X6 is selected from the group comprising Asp, Gln and Glu.

Priority: GB20050000643 Applic. Date: 2005-01-13; US2007-795135 Applic. Date: 2007-07-12; WO2006GB00051 Applic. Date: 2006-01-06

Inventor: FERGUSON MARK W J [GB]; OCCLESTON NICK [GB]; DEAKIN AMANDA [GB]; O'KANE SHARON [GB]


Application No.: US20120238506A1  Published: 20/Sep/2012

Title: ACACIA MACROSTACHYA SEED EXTRACT AND COMPOSITIONS CONTAINING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: 13/512578   Filing Date: 30/Nov/2010

Abstract:

The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the Skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.

Priority: FR20090058525 Applic. Date: 2009-11-30; WO2010EP68574 Applic. Date: 2010-11-30

Inventor: MSIKA PHILIPPE [FR]; SAUNOIS ALEX [FR]; LECLERE-BIENFAIT SOPHIE [FR]; BAUDOIN CAROLINE [FR]


Application No.: US20120240408A1  Published: 27/Sep/2012

Title: POLYETHYLENE GLYCOL CONTAINING COMPOSITION FOR SHAVING

Applicant/Assignee: KONINKLIJKE PHILIPS ELECTRONICS N.V

Application No.: 13/510126   Filing Date: 14/Dec/2010

Abstract:

The invention provides a composition comprising one or more low molecular weight polyethylene glycols (LMW-PEG) and one or more high molecular weight poly ethylene glycols (HMW-PEG), wherein the one or more LMW-PEGs have a molecular weight in a range of 200 to 500 dalton, and wherein the one or more HMW-PEGs have a molecular weight in a range of 8,000 to 45,000 dalton. Such composition can be used as a (friction reducing) shaving lotion or as a condom lubricant.

Priority: EP20090179791 Applic. Date: 2009-12-18; WO2010IB55806 Applic. Date: 2010-12-14

Inventor: HARVEY SEVERIN LUC RAMSES [NL]; LELIEVELD MARK JOHANNES [NL]; ZUIDERVAART JASPER [NL]


Application No.: US20120244095A1  Published: 27/Sep/2012

Title: COMPOSITIONS CONTAINING POLYMERIC, IONIC COMPOUNDS COMPRISING IMIDAZOLIUM GROUPS

Applicant/Assignee: BASF SE

Application No.: 13/427287   Filing Date: 22/Mar/2012

Abstract:

The present invention relates to compositions containing polymeric, ionic compounds comprising imidazolium groups. In particular, it relates to the use of polymeric, ionic compounds comprising imidazolium groups in personal care compositions and/or in biocide compositions.

Priority: US201161466493P Applic. Date: 2011-03-23

Inventor: KONRADI RUPERT [DE]; SIEMER MICHAEL [DE]; SOBOTKA BETTINA [DE]; KOLTZENBURG SEBASTIAN [DE]; HABERECHT MONIKA [DE]


Application No.: US20120244103A1  Published: 27/Sep/2012

Title: REVERSIBLE ORAL ADHESIVE GEL

Applicant/Assignee:

Application No.: 13/394109   Filing Date: 30/Aug/2010

Abstract:

The invention relates to a reversible oral adhesive gel. The reversible oral adhesive gel is suitable for application to lips to inhibit oral (mouth) breathing and to promote nasal breathing and thereby prevent or ameliorate snoring and to correct other respiratory problems.

Priority: AU20090904239 Applic. Date: 2009-09-04; WO2010IB02321 Applic. Date: 2010-08-30

Inventor: DAVIS ROBERT J [AU]; STATON JOHN ALEXANDER [AU]; ORBAN GEORGE JOHN [AU]


Application No.: US20120245079A1  Published: 27/Sep/2012

Title: Treatment of Diseases Caused by Bacterial Exotoxins

Applicant/Assignee:

Application No.: 13/393603   Filing Date: 03/Sep/2010

Abstract:

Provided are high affinity T cell receptor variable regions that are useful for treating diseases caused by superantigens including atopic dermatitis, pneumonia and delayed wound healing. The variable regions contain mutants that result in high affinity binding to the superantigen.

Priority: US2009-239638P Applic. Date: 2009-09-03; WO2010US47782 Applic. Date: 2010-09-03

Inventor: KRANZ DAVID M [US]; SCHLIEVERT PATRICK [US]


Application No.: US20120245086A1  Published: 27/Sep/2012

Title: WNT10-Derived Peptide and Use Thereof

Applicant/Assignee: CAREGEN CO., LTD

Application No.: 13/393370   Filing Date: 24/Nov/2009

Abstract:

The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder using the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.

Priority: KR20090081817 Applic. Date: 2009-09-01; WO2009KR06933 Applic. Date: 2009-11-24

Inventor: CHUNG YOUNG JI [KR]; KIM EUN MI [KR]; SONG SANG SU [KR]; CHO KYOUNG MI [KR]


Application No.: US20120245097A1  Published: 27/Sep/2012

Title: USE OF PEDF-DERIVED POLYPEPTIDES FOR PROMOTING STEM CELLS PROLIFERATION AND WOUND HEALING

Applicant/Assignee:

Application No.: 13/428996   Filing Date: 23/Mar/2012

Abstract:

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Priority: TW100109945 Applic. Date: 2011-03-23

Inventor: TSAO YEOU-PING [TW]; HO TSUNG-CHUAN [TW]


Application No.: US20120251480A1  Published: 04/Oct/2012

Title: Oil-In-Water External Skin Preparation

Applicant/Assignee: SHISEIDO COMPANY LTD

Application No.: 13/439071   Filing Date: 04/Apr/2012

Abstract:

The present invention provides an oil-in-water external skin preparation having thread-forming property and an excellent time-dependent stability of the thread-forming property, penetrating well into skin, providing richness and no stickiness when the applied preparation gets dry. The oil-in-water external skin preparation includes (a) 0.01 to 3.0% by mass of polyacrylic acid or metal salt thereof, (b) 0.01 to 1.0% by mass of alkyl-modified carboxyvinyl polymer, (c) 1.0 to 10.0% by mass of polyethylene glycol having an average molecular weight of 1000 or more to 50000 or less of, and (d) 0.5 to 20.0% by mass of oil.

Priority: JP20080143428 Applic. Date: 2008-05-30; US2010-995189 Applic. Date: 2010-11-30; WO2009JP59958 Applic. Date: 2009-06-01

Inventor: SUZUKI KAZUNOBU [JP]; SUGAHARA MISATO [JP]; ISHINO HIROKAZU [JP]; MASUDA MASAHIKO [JP]


Application No.: US20120251503A1  Published: 04/Oct/2012

Title: METHODS OF USING CHIMERIC COILED-COIL MOLECULE

Applicant/Assignee: APROGEN, INC

Application No.: 13/474439   Filing Date: 17/May/2012

Abstract:

The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.

Priority: US2010-728158 Applic. Date: 2010-03-19; US2007-576146 Applic. Date: 2007-03-27; WO2005IB03655 Applic. Date: 2005-09-28; US2004-614136P Applic. Date: 2004-09-28

Inventor: KOH GOU YOUNG [KR]; CHO CHUNG-HYUN [KR]


Application No.: US20120251510A1  Published: 04/Oct/2012

Title: AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD

Applicant/Assignee:

Application No.: 13/503329   Filing Date: 28/Oct/2010

Abstract:

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

Priority: JP20090247143 Applic. Date: 2009-10-28; WO2010JP69133 Applic. Date: 2010-10-28

Inventor: TAMAI KATSUTO [JP]; KANEDA YASUFUMI [JP]; YAMAZAKI TAKEHIKO [JP]; CHINO TAKENAO [JP]; SAGA KOTARO [JP]; ENDO MAYUMI [JP]


Application No.: US20120251613A1  Published: 04/Oct/2012

Title: METHOD FOR TREATING VITILIGO WITH A PROSTAGLANDIN ANALOGUE

Applicant/Assignee: AGILA SPECIALITIES PVT. LTD

Application No.: 13/194458   Filing Date: 29/Jul/2011

Abstract:

A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2[alpha] ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.

Priority: IN2011DE00861 Applic. Date: 2011-03-29; IN2011DE01639 Applic. Date: 2011-06-09

Inventor: JAIN RAJEEV [IN]; NARANG TARUN [IN]; CHETLAPALLI SATYA SRINIVAS [IN]


Application No.: US20120252735A1  Published: 04/Oct/2012

Title: TREATMENT OF SKIN CONDITIONS BY DICKKOPF1 (DKK1)

Applicant/Assignee: THE GOVT. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES

Application No.: 13/492990   Filing Date: 11/Jun/2012

Abstract:

The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin pigmentation, and/or decreasing hair growth. In particular, disclosed herein are methods of using topical administration of DKK1 to increase skin thickness, decrease skin pigmentation, or reduce hair growth. Also disclosed are topical DKK1 compositions for inducing non-palmoplantar skin to develop a palmoplantar phenotype.

Priority: US2009-518052 Applic. Date: 2009-06-05; WO2007US86855 Applic. Date: 2007-12-07; US2006-873874P Applic. Date: 2006-12-07

Inventor: HEARING VINCENT [US]; YAMAGUCHI YUJI [JP]; PASSERON THIERRY [FR]


Application No.: US20120258919A1  Published: 11/Oct/2012

Title: Collagen peptide, dipeptide and malady inhibitor

Applicant/Assignee: NITTA GELATIN INC

Application No.: 13/523438   Filing Date: 14/Jun/2012

Abstract:

A problem that the present invention is to solve is to provide: a main body of a peptide molecule which is effective for inhibition of various maladies such as osteoporosis, osteoarthritis and pressure ulcer, particularly, a dipeptide which is easy to absorb into a body in an intestine

a collagen peptide which comprises the dipeptide as an essential dipeptide

and a malady inhibitor which comprises the dipeptide as an essential effective component. As a means of solving such a problem, a collagen peptide according to the present invention is characterized by comprising a dipeptide having a structure of Hyp-Gly as an essential dipeptide. A dipeptide according to the present invention is characterized by having a structure of Hyp-Gly. A malady inhibitor according to the present invention is characterized by comprising a dipeptide having a structure of Hyp-Gly as an essential effective component.

Priority: JP20080254552 Applic. Date: 2008-09-30; US2009-443298 Applic. Date: 2009-03-27; WO2008JP71164 Applic. Date: 2008-11-14

Inventor: SUGIHARA FUMIHITO [JP]; INOUE NAOKI [JP]; KOIZUMI SEIKO [JP]; LIU CHINFANG [JP]; TAKASAKI HAJIME [JP]; KOBAYASHI HISAYUKI [JP]; MANO HIROSHI [JP]; NAKATANI SACHIE [JP]; WADA MASAHIRO [JP]


Application No.: US20120263671A1  Published: 18/Oct/2012

Title: AQUEOUS COSMETIC PREPARATION

Applicant/Assignee: KAO CORPORATION

Application No.: 13/536166   Filing Date: 28/Jun/2012

Abstract:

A method for producing an aqueous cosmetic composition containing the following components (A), (B) and (C): (A) a primary amine, a secondary amine, a tertiary amine or a quaternary amine having 12 to 60 carbons in total, (B) an anionic polymer having a carboxyl group, and (C) water, and, containing: a liquid crystal constituted by the components (A), (B) and (C)

obtained by mixing the components (A), (B) and (C)

heating the mixture to a temperature equal to or higher than the melting point of the component (A) to homogenize the mixture

and neutralizing the component (B) with the component (A) to form a salt.

Priority: JP20090298191 Applic. Date: 2009-12-28; WO2010JP73574 Applic. Date: 2010-12-27

Inventor: OKUBO KOJI [JP]


Application No.: US20120264682A1  Published: 18/Oct/2012

Title: TISSUE PROTECTIVE PEPTIDES AND USES THEREOF

Applicant/Assignee: ARAIM PHARMACEUTICALS, INC

Application No.: 13/448345   Filing Date: 16/Apr/2012

Abstract:

Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO

methods for treating or preventing a disease or disorder using tissue protective peptides

and methods for enhancing excitable tissue function using tissue protective peptides.

Priority: US201113278131 Applic. Date: 2011-10-20; US2008-997898 Applic. Date: 2008-10-29; WO2006US31061 Applic. Date: 2006-08-07; US2005-705741P Applic. Date: 2005-08-05; US2005-706276P Applic. Date: 2005-08-08; US2006-831737P Applic. Date: 2006-07-18

Inventor: CERAMI ANTHONY [US]; BRINES MICHAEL [US]; COLEMAN THOMAS [US]


Application No.: US20120264693A1  Published: 18/Oct/2012

Title: COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF

Applicant/Assignee: ZEALAND PHARMA A/S, THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE RESEARCH FOUNDATION OF STATE UNIVESITY OF NEWYORK

Application No.: 13/377773   Filing Date: 11/Jun/2010

Abstract:

Compounds capable of modulating intracellular gap junctional communication, as well as their use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC) 1 are disclosed.

Priority: WO2010DK00092 Applic. Date: 2010-06-11; EP20090007772 Applic. Date: 2009-06-12; US2009-187839P Applic. Date: 2009-06-17

Inventor: DELMAR MARIO [US]; TAFFET STEVEN M [US]; COOMBS WANDA [US]; VERMA VANDANA [US]; LARSEN BJARNE DUE [DK]


Application No.: US20120264696A1  Published: 18/Oct/2012

Title: PREVENTION OF CELLULAR SENESCENCE IN MAMMALS BY NATURAL PEPTIDE COMPLEXES

Applicant/Assignee: ISLAND KINETICS INC, ISLAND KINETICS, INC

Application No.: 13/400047   Filing Date: 18/Feb/2012

Abstract:

Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn

mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof

Priority: US201113084709 Applic. Date: 2011-04-12

Inventor: GUPTA SHYAM K [US]; WALKER LINDA [US]


Application No.: US20120269908A1  Published: 25/Oct/2012

Title: CARRIER IN OIL-IN-WATER EMULSION FORM, PARTICULARLY FOR COSMETIC OR DERMATOLOGICAL USE

Applicant/Assignee: OCTALIA TECHNOLOGIES

Application No.: 13/259398   Filing Date: 27/Nov/2009

Abstract:

The present invention relates to a carrier in oil-in-water emulsion form, containing a very small amount of a surface-active agent so that the emulsion is stable, well-tolerated, and nonirritating. The present invention also relates to a method for preparing a carrier according to the invention and to the use of such a carrier as a base for compositions to be applied onto sensitive human or animal body tissue, particularly in dermatological or dermocosmetic compositions.

Priority: FR20080058067 Applic. Date: 2008-11-27; WO2009FR52323 Applic. Date: 2009-11-27

Inventor: SARRAZIN CHRISTIAN [FR]; DO MARINA [FR]; BOIX MICHELE [FR]


Application No.: US20120270769A1  Published: 25/Oct/2012

Title: METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES

Applicant/Assignee:

Application No.: 13/503437   Filing Date: 22/Oct/2010

Abstract:

The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

Priority: WO2010US53767 Applic. Date: 2010-10-22; US2009-254434P Applic. Date: 2009-10-23

Inventor: MARSAULT ERIC [CA]; LEOGANE OLIVIER [CA]; MATHIEU AXEL [CA]; BEAUBIEN SYLVIE [CA]; LEDUC RICHARD [CA]


Application No.: US20120270796A1  Published: 25/Oct/2012

Title: Suspension Type Topical Formulations Comprising Cyclic Depsipeptide

Applicant/Assignee: NOVARTIS AG

Application No.: 13/445202   Filing Date: 12/Apr/2012

Abstract:

The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions.

Priority: US201161477297P Applic. Date: 2011-04-20

Inventor: HAUG CLAIRE [FR]


Application No.: US20120276087A1  Published: 01/Nov/2012

Title: METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Applicant/Assignee:

Application No.: 13/458896   Filing Date: 27/Apr/2012

Abstract:

Methods of treating, preventing, or managing autoimmune inflammatory diseases and disorders including but not limited to spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis by the administration of phosphodiesterase 4 (PDE4) inhibitors in combination with other therapeutics are disclosed. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US201161480263P Applic. Date: 2011-04-28

Inventor: SCHAFER PETER H [US]; GANDHI ANITA [US]; CAPONE LORI [US]


Application No.: US20120276126A1  Published: 01/Nov/2012

Title: LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES

Applicant/Assignee: AGENNIX AG

Application No.: 13/546208   Filing Date: 11/Jul/2012

Abstract:

The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.

Priority: US2010-964327 Applic. Date: 2010-12-09; US2003-434769 Applic. Date: 2003-05-09; US2002-379442P Applic. Date: 2002-05-10; US2002-379441P Applic. Date: 2002-05-10; US2002-379474P Applic. Date: 2002-05-10

Inventor: VARADHACHARY ATUL [US]; BARSKY RICK [US]; PERICLE FEDERICA [US]; PETRAK KAREL [US]; WANG YENYUN [US]


Application No.: US20120277143A1  Published: 01/Nov/2012

Title: IL4/IL13 Binding Repeat Proteins and Uses

Applicant/Assignee:

Application No.: 13/458578   Filing Date: 27/Apr/2012

Abstract:

IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.

Priority: US201161480999P Applic. Date: 2011-04-29; US201161481008P Applic. Date: 2011-04-29; US201161481021P Applic. Date: 2011-04-29

Inventor: JACOBS STEVEN [US]; O'NEIL KARYN [US]; BAUMANN MICHAEL [CH]; SENNHAUSER GABY [CH]


Application No.: US20120282319A1  Published: 08/Nov/2012

Title: LOTIONED WIPE PRODUCT TO REDUCE ADHESION OF SOILS OR EXUDATES TO THE SKIN

Applicant/Assignee:

Application No.: 13/548565   Filing Date: 13/Jul/2012

Abstract:

An anti-stick agent that may be incorporated into an aqueous medium to assist in the prevention of soils and bodily exudates adhering to the skin. A substrate may be utilized to assist in delivering the anti-stick agent to the skin.

Priority: US2007-807288 Applic. Date: 2007-05-25; US2006-812828P Applic. Date: 2006-06-12; US2006-855426P Applic. Date: 2006-10-31

Inventor: MARSH RANDALL GLENN [US]; SAWIN PHILIP ANDREW [US]; WATSON RANDALL ALAN [US]


Application No.: US20120289452A1  Published: 15/Nov/2012

Title: COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NECROSIS

Applicant/Assignee: ILANA NATHAN

Application No.: 13/164870   Filing Date: 21/Jun/2011

Abstract:

A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells.

Priority: IL20020148924 Applic. Date: 2002-03-26; US2004-509405 Applic. Date: 2004-09-24; WO2003IL00253 Applic. Date: 2003-03-26

Inventor: NATHAN ILANA [IL]; LICHTENSTEIN ALEXANDRA [IL]


Application No.: US20120289463A1  Published: 15/Nov/2012

Title: Compositions and Methods for Promoting Epithelialization and Wound Closure

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: 13/519551   Filing Date: 29/Dec/2010

Abstract:

Compositions for antagonizing phosphorylation and subsequent degradation of glycogen synthase kinase 3 beta (GSK3[beta]) in epidermal cells are disclosed. GSK3[beta] phosphorylation antagonists include molecules that function to inhibit or reduce the binding activity or enzymatic activity of an upstream signaling molecule leading to GSK3[beta] phosphorylation, or by downregulating the expression of one or more upstream signaling molecules involved in regulating GSK3[beta] phosphorylation. Methods of using the GSK3[beta] phosphorylation antagonists to inhibit or reduce the phosphorylation and degradation of GSK3[beta] in epidermal cells are provided. The methods are useful to promote epithelialization and closure of wounds, such as chronic non-healing wounds.

Priority: US2009-291669P Applic. Date: 2009-12-31; WO2010US62361 Applic. Date: 2010-12-29

Inventor: TOMIC-CANIC MARJANA [US]; BREM HAROLD [US]


Application No.: US20120294820A1  Published: 22/Nov/2012

Title: CLEAR, WASHABLE LUBRICANT COMPOSITIONS AND METHODS OF MAKING SAME

Applicant/Assignee: CHEMSIL SILICONES, INC

Application No.: 13/482811   Filing Date: 29/May/2012

Abstract:

Bi- or multiphasic, clear or translucent silicone-containing lubricant compositions, and products including such compositions and methods of making such compositions and products are disclosed. The refractive index of each immiscible phase of the lubricant composition is matched to that of each other phase to make the composition clear or translucent. The compositions are highly lubricious, non-staining, and easily washable.

Priority: US2009-586198 Applic. Date: 2009-09-18; US2008-113623P Applic. Date: 2008-11-12; US2008-200290P Applic. Date: 2008-11-26

Inventor: HARRISON JAMES JEFFRIES [US]; HERNANDEZ GUILLERMO [US]


Application No.: US20120301397A1  Published: 29/Nov/2012

Title: DIAGNOSIS OF MACROPHAGE MEDIATED DISEASE

Applicant/Assignee:

Application No.: 13/529823   Filing Date: 21/Jun/2012

Abstract:

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

Priority: US2006-648223 Applic. Date: 2006-12-29; US2002-138275 Applic. Date: 2002-05-02; US2001-288208P Applic. Date: 2001-05-02

Inventor: LOW PHILIP S [US]; TURK MARY JO [US]


Application No.: US20120315229A1  Published: 13/Dec/2012

Title: CLARIFYING AGENTS FOR ORGANOMODIFIED SILICONES

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS INC

Application No.: 13/156499   Filing Date: 09/Jun/2011

Abstract:

There is provided herein a composition comprising a silicone copolymer of the general formula (I) MaMEcDdDEeTfTEgQh where M=R1R2R3SiO1/2

ME=R4R5RESiO1/2

D=R6R7SiO2/2

DE=R8RESiO2/2

T=R9RESiO2/2

T=R9SiO3/2

TE=RESiO2/2

and Q=SiO4/2

where R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently selected from the group of monovalent hydrocarbon radicals optionally containing heteroatoms, carbonyl groups, and hydroxyl groups, each independently having from about 1 to about 20 carbon atoms

RE is a monovalent radical defined as: -R10O-(C2H4O)h(C3H6O)i(C4H8O)i-R11 or -R12 with the provision that the copolymer must contain at least one RE group

R10 is a linear or branched divalent hydrocarbon radical containing from 3 to about 10 carbon atoms

R11 is H or -C(-O)CH3 or a monovalent saturated or unsaturated hydrocarbon radical, optionally containing heteroatoms and hydroxyl groups, containing from 1 to about 30 carbon atoms

R12 is a hydrocarbon radical, containing from 2 to about 30 carbon atoms and at least 1 hydroxyl group, optionally containing heteroatoms

subscripts a, b, c, d, e, f, and g are 0 or positive subject to the limitation a+b+c+d+e+f+g<1000

subscripts h, i, and j are 0 or positive subject to the limitation h+i+j is less than 100

and, b) an organic oil containing at lease 1 ester group -C(-O)O- which exhibits Hansen solubility parameters of 14<[delta]D<18, 4<[delta]H<10 and 3<[delta]P<15, and wherein the composition has a viscosity of less than 20,000 cps. There are also provided silicone emulsions containing the composition, a personal care composition containing said silicone emulsion, and a process of treating a silicone surfactant comprising mixing the contents of the composition.

Priority:

Inventor: FALK BENJAMIN [US]; GONZALEZ SIGFREDO [US]


Application No.: US20120315234A1  Published: 13/Dec/2012

Title: COMPOSITION FOR HAIR AND BODY APPLICATION

Applicant/Assignee: EQYSS GROOMING PRODUCTS

Application No.: 13/532536   Filing Date: 25/Jun/2012

Abstract:

The inventive compositions comprise in a deionized water base, a composition comprising: a preservative, a chelating agent

one or more moisturizer and hydrolyzed keratin protein

an antioxidant selected from the group consisting of citric acid and a vitamin E salt

and an emulsifier-water trap selected from the group consisting of cetearyl alcohol and glyceryl stearate

and PEG-40 castor oil. The composition, which is in liquid form, may be applied in the form of a spray or mist by dipping the affected area in the liquid or by pouring a small amount of the liquid onto the hair or body to be treated.

Priority: US2007-953854 Applic. Date: 2007-12-10; US2005-253968 Applic. Date: 2005-10-19; US2004-522603P Applic. Date: 2004-10-19

Inventor: VAN DON [US]; VAN KEMPEN DALLAS [US]


Application No.: US20120321575A1  Published: 20/Dec/2012

Title: USE OF KIF13A AND AP-1 INHIBITORS FOR INHIBITING MELANOGENESIS

Applicant/Assignee: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Application No.: 13/569576   Filing Date: 08/Aug/2012

Abstract:

The present invention relates to novel pharmaceutical or cosmetic compositions comprising at least one inhibitor of a sub-unit of AP-1 adaptor complex, of a kinesin interacting with AP-1, in particular Kif13A, or of the interaction between a sub-unit of AP-1 adaptor complex and said kinesin, as well as the use of same to manufacture a drug intended for the treatment of pigmentary disorders and as a depigmentation agent.

Priority: FR20080052692 Applic. Date: 2008-04-22; FR20080052696 Applic. Date: 2008-04-22; US2010-988570 Applic. Date: 2010-10-19; WO2009FR50737 Applic. Date: 2009-04-21

Inventor: RAPOSO GRACA [FR]; DELEVOYE CEDRIC [FR]; TENZA DANIELE [FR]; HURBAIN ILSE [FR]


Application No.: US20120328553A1  Published: 27/Dec/2012

Title: METHOD AND ANTIBACTERIAL/ANTIMICROBIAL COMPOSITIONS IN DENTAL COMPOSITIONS

Applicant/Assignee: DENTSPLY INTERNATIONAL INC

Application No.: 13/530248   Filing Date: 22/Jun/2012

Abstract:

Disclosed herein is a composition and method of making a polymerizable antibacterial/antimicrobial resin and using such a bioactive resin in formulated dental compositions.

Priority: US201161499910P Applic. Date: 2011-06-22

Inventor: JIN XIAOMING [US]


Application No.: US20120328632A1  Published: 27/Dec/2012

Title: INHIBITION OF LEUKOCYTE ADHESION

Applicant/Assignee: GENENTECH, INC

Application No.: 13/332881   Filing Date: 21/Dec/2011

Abstract:

This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.

Priority: US201113106122 Applic. Date: 2011-05-12; US2010-807417 Applic. Date: 2010-09-03; US2010-688123 Applic. Date: 2010-01-15; US2007-904157 Applic. Date: 2007-09-26; US2003-342587 Applic. Date: 2003-01-15; US1997-967243 Applic. Date: 1997-11-05; US1994-256418 Applic. Date: 1994-07-11; WO1994US03791 Applic. Date: 1994-04-06; US1993-056454 Applic. Date: 1993-05-03

Inventor: LASKY LAURENCE A [US]; BAUMHUETER SUSANNE [US]; ROSEN STEVEN D [US]; SINGER MARK S [US]


Application No.: US20120328635A1  Published: 27/Dec/2012

Title: CHAPERONIN 10 VARIANTS

Applicant/Assignee: CBIO LIMITED

Application No.: 13/500159   Filing Date: 08/Oct/2010

Abstract:

The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).

Priority: AU20090904956 Applic. Date: 2009-10-09; WO2010AU01327 Applic. Date: 2010-10-08

Inventor: NAYLOR DEAN JASON [AU]; BROWN RICHARD JAMES [AU]; HOWARD CHRISTOPHER BRUCE [AU]; DE BAKKER CHRISTOPHER JOHN [AU]; STOK JEANETTE ELIZABETH [AU]; JAMES ANDREW LEIGH [AU]; LAMBERT DANIEL SCOTT [AU]; RALSTON KYLIE JANE [AU]; VAN HEUMEN WALTER RENE ANTONIUS [AU]; WARD LINDA ALLISON [AU]


Application No.: US20120328636A1  Published: 27/Dec/2012

Title: KDR PEPTIDES AND VACCINES COMPRISING THE SAME

Applicant/Assignee: ONCOTHERAPY SCIENCE, INC

Application No.: 13/494933   Filing Date: 12/Jun/2012

Abstract:

The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12

nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46

and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.

Priority: JP20020267285 Applic. Date: 2002-09-12; JP20030062003 Applic. Date: 2003-03-07; JP20030167042 Applic. Date: 2003-06-11; US2010-711159 Applic. Date: 2010-02-23; US2009-355616 Applic. Date: 2009-01-16; US2003-527496 Applic. Date: 2003-09-12; WO2003JP11722 Applic. Date: 2003-09-12

Inventor: TAHARA HIDEAKI [JP]; WADA SATOSHI [JP]; TSUNODA TAKUYA [JP]

Clck to enlarge and view details
US Patent Applications  in 2013
 
US Patent Applications  in 2011
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..